|
Austria-Vi-Vi Azienda Directories
|
Azienda News:
- Lung Cancer - Medscape
Lung Cancer : Review in-depth clinical information, latest medical news, and guidelines on lung cancer, specifically small-cell lung cancer and non-small-cell lung cancer Read the latest
- Small Cell Lung Cancer in 2024: Treatment Advances - Medscape
Amgen Drug Cuts Small Cell Lung Cancer Death Risk by 40%; Moving Earlier in the Disease Landscape: Understanding Adjuvant Immunotherapy for Non-Small Cell Lung Cancer 0 25 CME ABIM MOC Credits
- ASCO 2025: Key Highlights in Advanced Lung Cancer - Medscape
In extensive-stage small cell lung cancer, tarlatamab demonstrated superiority over chemotherapy in the DeLLphi-304 trial, with favorable patient-reported outcomes including improved cough and
- Advanced Non-Small Cell Lung Cancer Updates From ASCO 2024 - Medscape
Practice-changing studies in advanced non-small cell lung cancer presented at ASCO 2024 are reviewed by Dr Ticiana Leal, including the phase 3 LAURA and PALOMA-3 studies and a 5-year update of CROWN
- Two Lung Cancer Drugs Recommended by EMA - Medscape
Is Consolidation Osimertinib Superior to Durvalumab in EGFR-Mutated Non–Small Cell Lung Cancer? Small Cell Lung Cancer in 2024: Treatment Advances 3090D553-9492-4563-8681-AD288FA52ACE
- Changes in the Treatment Landscape of Early-Stage Non-Small Cell Lung . . .
Dr Narjust Florez explores the transformative shifts in the treatment landscape for early-stage non–small cell lung cancer over the years, particularly emphasizing the significant changes
- Why a New Inhalable Lung Cancer Treatment Is So Promising - Medscape
Evolving Treatment for Small Cell Lung Cancer; Fast Five Quiz: Small Cell Lung Cancer; SLIDESHOW Brain Lesions: Summaries of 12 Cases; Expert Commentary Why Lung Cancer Screening Is Not for
- Zenocutuzumab Effective Against NRG1 Fusion Cancers - Medscape
IASLC Issues Consensus on Neoadjuvant, Adjuvant Treatments in Non–Small Cell Lung Cancer Is Consolidation Osimertinib Superior to Durvalumab in EGFR-Mutated Non–Small Cell Lung Cancer
- Potential Drivers of LCINS - Medscape
During a plenary session at the 2024 World Congress on Lung Cancer, experts addressed the known and suspected causes of LCINS, including fallout from climate change, vaping, cannabis use, and
- Evaluation and Management of Small Pulmonary Nodules - Page 3 - Medscape
Lung nodules in the right lung and in the upper lobes have a higher probability for malignancy [ 17 , 45 ] Some studies indicate that 70% of all lung cancers are located in the upper lobes
|
|